NVAX Quote, Financials, Valuation and Earnings

Halozyme Therapeutics has a net margin of -143.53% compared to Novavax's net margin of 47.23%. Novavax's return on equity of -- beat Halozyme Therapeutics's return on equity of 156.62%.

Novavax has a consensus price target of $16.00, signalling upside risk potential of 88.01%. On the other hand Halozyme Therapeutics has an analysts' consensus of $64.13 which suggests that it could grow by 34.89%. Given that Novavax has higher upside potential than Halozyme Therapeutics, analysts believe Novavax is more attractive than Halozyme Therapeutics.

Novavax has a beta of 2.017, which suggesting that the stock is 101.749% more volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.226, suggesting its more volatile than the S&P 500 by 22.555%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Novavax quarterly revenues are $84.5M, which are smaller than Halozyme Therapeutics quarterly revenues of $290.1M. Novavax's net income of -$121.3M is lower than Halozyme Therapeutics's net income of $137M. Notably, Novavax's price-to-earnings ratio is -- while Halozyme Therapeutics's PE ratio is 15.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.48x versus 6.52x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -143.53% compared to Novavax's net margin of -31993.31%. Novavax's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -98.72%.

Novavax has a consensus price target of $16.00, signalling upside risk potential of 88.01%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $10.67 which suggests that it could grow by 482.88%. Given that Inovio Pharmaceuticals has higher upside potential than Novavax, analysts believe Inovio Pharmaceuticals is more attractive than Novavax.

Novavax has a beta of 2.017, which suggesting that the stock is 101.749% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.749, suggesting its less volatile than the S&P 500 by 25.086%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

Novavax quarterly revenues are $84.5M, which are larger than Inovio Pharmaceuticals quarterly revenues of $100.8K. Novavax's net income of -$121.3M is lower than Inovio Pharmaceuticals's net income of -$25.2M. Notably, Novavax's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.48x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -143.53% compared to Novavax's net margin of 0.7%. Novavax's return on equity of -- beat Moderna's return on equity of -17.44%.

Novavax has a consensus price target of $16.00, signalling upside risk potential of 88.01%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.23%. Given that Novavax has higher upside potential than Moderna, analysts believe Novavax is more attractive than Moderna.

Novavax has a beta of 2.017, which suggesting that the stock is 101.749% more volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novavax pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Novavax quarterly revenues are $84.5M, which are smaller than Moderna quarterly revenues of $1.9B. Novavax's net income of -$121.3M is lower than Moderna's net income of $13M. Notably, Novavax's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.48x versus 3.08x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -143.53% compared to Novavax's net margin of 25.23%. Novavax's return on equity of -- beat Pfizer's return on equity of 4.63%.

Novavax has a consensus price target of $16.00, signalling upside risk potential of 88.01%. On the other hand Pfizer has an analysts' consensus of $31.86 which suggests that it could grow by 19.16%. Given that Novavax has higher upside potential than Pfizer, analysts believe Novavax is more attractive than Pfizer.

Novavax has a beta of 2.017, which suggesting that the stock is 101.749% more volatile than S&P 500. In comparison Pfizer has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.739%.

Novavax has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.28% to investors and pays a quarterly dividend of $0.42 per share. Novavax pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Novavax quarterly revenues are $84.5M, which are smaller than Pfizer quarterly revenues of $17.7B. Novavax's net income of -$121.3M is lower than Pfizer's net income of $4.5B. Notably, Novavax's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novavax is 1.48x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.